Overview

Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma

Status:
Unknown status

Trial end date:
2020-02-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effects of daratumumab monotherapy on bone disease in patients with relapsed/refractory MM who have received at least 2 prior lines of therapy, including lenalidomide and a PI.

Phase:

Phase 2

Details

Lead Sponsor:

Hellenic Society of Hematology

Collaborator:

Janssen Pharmaceuticals

Treatments:

Antibodies, Monoclonal
Daratumumab
Proteasome Inhibitors